An interventional study of Candida Albicans Antigen Injection in Alopecia Areata, sponsored by Universidad Autonoma de Nuevo Leon. Status unknown at 1 site in Mexico. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-08-21.
Sponsored by Universidad Autonoma de Nuevo Leon · Not applicable, Interventional, and Treatment
The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.
469 studies on the registry are indexed under Alopecia Areata; 91 are open to participants now.
This study's planned enrollment of 30 is below the median of 50 across 381 interventional studies indexed under Alopecia Areata.
Browse Alopecia Areata studies →Universidad Autonoma de Nuevo Leon is the lead sponsor of 53 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Triamcinolone acetonide will be administered intralesionally at a concentration of 4 mg/mL. The solution will be injected in 0.1 mL doses, spaced 1 cm apart. The maximum total dose per session will be limited to 3 mL
Drug: Candida Albicans Antigen Injection
Single subcutaneous administration of 0.1 mL of Candida albicans antigen into one of the alopecic patches
Drug: Candida Albicans Antigen Injection
subcutaneous administration of Candida albicans antigen
Treatment response
porcentage of hair growth determined by SALT score
Time frame: 5 months
Side effects
Side effects associated to the treatment
Time frame: 5 months
Plan to share: Undecided — The database with the main clinical and trichoscopic results could be shared
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Jul 2025, 11 months after the start.
Of 56 non-industry interventional studies with no phase under Alopecia Areata, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's planned 11 months is close to that.
Counting every sponsor, half of 89 studies reached it within 11 months; a quarter within 6 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Candida albicans Antigen Injection
Universidad Autonoma de Nuevo Leon